AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

Core Insights - AbelZeta Pharma announced preliminary results from the C-CAR031 study, showing a disease control rate (DCR) of 91.3% and an objective response rate (ORR) of 56.5% in patients with advanced hepatocellular carcinoma (HCC) [1][2][5] Group 1: Study Results - The study reported that 91.3% of patients experienced tumor reductions, with a median reduction of 42.2% [2][5] - The ORR was 75.0% at dose level 4 (DL4) [1][2] - The median overall survival (mOS) was estimated at 11.14 months with a follow-up of 9.03 months [2][5] Group 2: Safety Profile - No dose-limiting toxicity or immune effector cell associated neurotoxicity syndrome (ICANS) was observed [3] - Cytokine release syndrome (CRS) occurred in 91.7% of patients, with the majority being grade 1/2 [3] Group 3: Product Information - C-CAR031 is an autologous, armored GPC3-targeting CAR-T therapy developed for HCC, co-developed by AbelZeta and AstraZeneca [4][6] - The therapy utilizes a novel GPC3-targeting CAR-T designed by AstraZeneca and is manufactured by AbelZeta in China [4][6] Group 4: Company Overview - AbelZeta Pharma is a global clinical-stage biopharmaceutical company focused on innovative cell-based therapeutic products [6] - The company operates in Rockville, Maryland, and Shanghai, China, with a commitment to developing treatments for hematological malignancies and solid tumors [6]